Focused On-demand Library for Lanosterol synthase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

2,3-epoxysqualene--lanosterol cyclase; Oxidosqualene--lanosterol cyclase

Alternative UPACC:

P48449; B4DJZ9; D3DSN0; E9PEI9; G5E9Q9; Q8IYL6; Q9UEZ1


Lanosterol synthase, also known as 2,3-epoxysqualene--lanosterol cyclase, plays a pivotal role in the cholesterol biosynthesis pathway by catalyzing the conversion of (S)-2,3 oxidosqualene to lanosterol. This enzyme is crucial for the formation of the sterol nucleus, laying the foundation for the synthesis of all steroids.

Therapeutic significance:

The enzyme's involvement in conditions such as Cataract 44, Hypotrichosis 14, and Alopecia-intellectual disability syndrome 4 highlights its potential as a therapeutic target. Understanding the role of Lanosterol synthase could open doors to potential therapeutic strategies for these diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.